Articles

EGFR and MET Combined Inhibition in EGFR-Mutated Advanced NSCLC: A Real-World Study

ASCO 2021 – Lung Cancer

The combination of EGFR-tyrosine kinase inhibitor (TKI) and MET-TKI therapy improves clinical outcomes in patients who developed MET amplification after prior EGFR-TKI therapy in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

CheckMate-9LA: Nivolumab + Ipilimumab in Advanced NSCLC – Two-Year Update

ASCO 2021 – Lung Cancer

First-line use of nivolumab + ipilimumab in patients with advanced non–small-cell lung cancer (NSCLC) offers durable survival relative to chemotherapy alone with ≥2 years of follow-up. Read More ›

Racial Disparities in Lung Adenocarcinoma: The Contribution of African Ancestry

ASCO 2021 – Lung Cancer

Findings of a global ancestry analysis confirm that African ancestry is associated with worse survival outcomes among patients with lung adenocarcinoma. Read More ›

Clinical Trial Enrollment and Biomarker Testing in NSCLC: Racial Disparities

ASCO 2021 – Lung Cancer

Comprehensive biomarker testing and clinical trial participation rates were significantly lower for black patients in the United States compared with white patients with advanced non–small-cell lung cancer (NSCLC). Read More ›

CheckMate-227: Nivolumab plus Ipilimumab in Advanced NSCLC – Four-Year Update

ASCO 2021 – Lung Cancer

Nivolumab in combination with ipilimumab delivers durable, long-term survival benefit versus chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) regardless of PD-L1 expression with 4 years of follow-up. Read More ›

GEOMETRY Mono-1: Capmatinib in MET Exon 14–Mutated Advanced NSCLC

ASCO 2021 – Lung Cancer

Deep and durable responses with a manageable toxicity profile were achieved with capmatinib treatment in patients with MET exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy. Read More ›

Videos Year in Review

Key Abstracts from ASCO 2021 in NSCLC

By Mark A. Socinski, MD

AACR & ASCO 2021 – Midyear Review

Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Read More ›

Year in Review

Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)

AACR & ASCO 2021 – Midyear Review

Adjuvant atezolizumab extends disease-free survival after adjuvant chemotherapy compared with best supportive care after adjuvant chemotherapy in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC). Read More ›

Year in Review

2021 Midyear Review: Non–Small-Cell Lung Cancer

AACR & ASCO 2021 – Midyear Review

Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing. Read More ›

Year in Review

Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)

AACR & ASCO 2021 – Midyear Review

Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone. Read More ›

Articles

Page 48 of 147